Kobayashi Pharmaceutical Red Yeast Rice Health Product Incident Escalates: 5 Dead, 289 Injured, Thousands Affected, Compensation Process Officially Launched, Economic Losses May Be Astronomical!
Japanese company Kirin Pharmaceutical has officially launched a compensation process for individuals who may have suffered health damages due to consuming its red yeast rice health supplements, covering medical expenses and compensation for emotional distress. The company has explicitly stated that the scope of compensation is limited to "individuals who have developed kidney diseases or other symptoms after taking the supplement and whose causal relationship has been medically confirmed." The company will implement special measures for cases where individuals have passed away due to consuming the product.
The red yeast rice health supplement incident at Kirin Pharmaceutical has resulted in a series of serious consequences: as of June 26, five people have unfortunately passed away, 289 have received inpatient treatment (including those who have been discharged), and 1,656 have visited medical institutions for check-ups. Additionally, the company has received consultations from 170 deceased consumers' families, of whom 76 had taken Kirin's red yeast rice health supplement prior to their deaths, but the causal relationship between their deaths and the supplement is still under investigation. Three of the deceased have been confirmed not to have any relationship with taking red yeast rice health supplement, while the remaining 91 deceased did not take the product. Therefore, the confirmed number of direct deaths related to Kirin's red yeast rice health supplement is currently 5, while 76 deaths may be related to the product, with the specific circumstances still under further investigation. This incident has resulted in at least 5 deaths, hundreds of hospitalizations, and may involve more deaths, which has aroused great concern and worry among the Japanese government and public.
This compensation process was taken after a series of reports about red yeast rice health supplements and serious health problems, including deaths. Prior to this, Kobayashi Pharmaceutical Company had voluntarily recalled the product and faced strict scrutiny. It is currently impossible to estimate how many people will file claims and how much economic loss Kobayashi Pharmaceutical Company may ultimately bear.
Looking for chemical products? Let suppliers reach out to you!
2026-07-23
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
Middle East Conflict Pushes Up Oil Prices as More Than 100 Chemical Raw Materials Rise in Concentration
-
Redwall Raises Prices by as Much as 80%, Songwon Launches Global Increases, and Chemical Companies Are Collectively Passing On Costs
-
UAE Breaks Ground on World’s First Gigascale Round-the-Clock Renewable Energy Project, Setting a New Global Standard For Clean Energy
-
“Oil Sheikhs” Buy Germany’s Chemical Crown: A €14.7 Billion Green Gamble or a Power Play in the Age of Carbon Neutrality?
-
From “10,000-Ton Bet” to “5,000-Ton Test”: Acore’s Polyetheramine Dilemma—Is This a Symptom of Industry Winter or the Prelude to Strategic Retreat?
-
Kraton Announces Strategic Plan to Streamline Polymer Operations in Berre, France
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
Canada’s Acynonapyr Review Offers More Than a New Mite Product
-
Global Ag M&A in 2025 Looked Less Like Expansion and More Like Selection
Recommend Reading
-
Hormuz Is Reopening, But Chemical Logistics May Take Months to Recover
-
Japanese Plastics Market Accelerates its Shifts to Recycled Materials and Bioplastics
-
Synthomer Sells Its Last Upstream Chemical Business
-
Wuxi Yinda Nylon Acquires German Century-Old Chemical Giant Perlon
-
India Swings the Tariff Axe at Made-in-China: Epoxy Resins Are Just the Beginning—The Road for Chinese Chemicals Abroad Is No Longer Smooth
-
Insufficient Spot Buying Interest, Acrylonitrile Market Slips Again in China
-
Premium Global Chemical Sourcing Requests (19 - 22 Mar, 2026)
-
Demand Changes Lead to Initial Drop and Then Rise in Butadiene Prices
-
Supply and Demand Game, Toluene Market Trend Stabilizes in China
-
Both Supply and Demand Weak & Inventory Pressures Keep PVC Market Volatile and Tend to Be Weak